Subcutaneous injections are less invasive than intramuscular ones
Retatrutide clinical trial data Retatrutide data comes primarily from two sources: a Phase 2 trial published in the New England Journal of Medicine and the Phase 3 TRIUMPH program that began reporting results in mid-2025
Sakamoto S, Hatakeyama M, Ito T, Handa H
Methylcellulose Capsule: Lp v vin nang thc vt an ton, ph hp cho ngi n chay, gip bo v hot cht bn trong v d dng hp th khi s dng
IMMUNIZATION: Mountebanks, Grifters, and Frauds (Oh My!): An Update on the Management of Vaccine-Preventable Illnesses in 2025 Jeff Aeschlimann, PharmD, University of Connecticut School of Pharmacy, Storrs, CT 0009-0000-25-069-L06-P (0.1 CEU or 1 contact hour) (Application-based) CE FINALE LIVE ENCORE WEBINARS AVAILABLE If you find you cannot make it to our LIVE EVENT on Friday, December 19 th , you can participate in our ENCORE LIVE WEBINARS that will be streamed on the following dates: Monday, December 22, 12:00 (Noon) - 1:00 pm NKOTB: New and Emerging Roles for GLP-1-Based Medications Monday, December 22, 7:00 pm-8:00 pm Hormone Therapys Twin Faces: Sorting Science from Misconception Monday, December 22, 8:10 9:10 pm LAW: Identifying Imposters: Counterfeit Drugs in the Pharmacy Distribution Chain Tuesday, December 23, 12:00 pm-1:00 pm PATIENT SAFETY: Biosimilar Doppelgangers Tuesday, December 23, 7 pm 8 pm IMMUNIZATION: Mountebanks, Grifters, and Frauds (Oh My!): An Update on the Management of Vaccine-Preventable Illnesses in 2025 Monday, December 29, 12:00 (Noon) 1:00 pm - Breaking the Mold: Novel Mechanisms in Psychiatrys New Kids on the Block Monday, December 29, 7 pm 8 pm LAW: Identifying Imposters: Counterfeit Drugs in the Pharmacy Distribution Chain Tuesday, December 30, 12:00 (Noon) 1:00 pm - NKOTB: 2025 Updates on Management of Hypertension in Adults Tuesday, December 30, 7 pm 8 pm - Step by Step: Tackling Imposter Syndrome in Every Transition A continuous class schedule format will be used
Progression of behavioral disturbances and neuropsychiatric symptoms in patients with genetic frontotemporal dementia
